Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Studies of Canakinumab in High-Risk Former-Smokers (CANIFS)

NCT06038526 is registered in ClinicalTrials.gov with Peter Shields as lead sponsor.

NCT NCT06038526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06038526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Studies of Canakinumab in High-Risk Former-Smokers (CANIFS)
Lead sponsor
Peter Shields
Phase
Phase 2
Overall status
Completed
Start date
March 11, 2024
Completion date
May 26, 2026
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cigarette smoking-related carcinoma, lung carcinoma